Cipher Pharmaceuticals Inc. (NASDAQ:CPHR) (TSE:CPH) was downgraded by research analysts at TD Securities from a “buy” rating to a “hold” rating in a report issued on Wednesday. They currently have a $3.50 price target on the stock, down from their prior price target of $7.50. TD Securities’ price objective points to a potential upside of 24.11% from the company’s current price.

Separately, GMP Securities reiterated a “hold” rating on shares of Cipher Pharmaceuticals in a report on Saturday, August 13th.

Shares of Cipher Pharmaceuticals (NASDAQ:CPHR) opened at 2.82 on Wednesday. The company’s market capitalization is $73.87 million. Cipher Pharmaceuticals has a 12-month low of $2.55 and a 12-month high of $6.37. The company has a 50 day moving average of $3.52 and a 200-day moving average of $4.65.

Cipher Pharmaceuticals (NASDAQ:CPHR) last posted its quarterly earnings data on Friday, November 11th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.07) by $0.01. Cipher Pharmaceuticals had a negative net margin of 64.97% and a negative return on equity of 8.75%. The business earned $9.30 million during the quarter, compared to analyst estimates of $10.42 million. On average, equities analysts anticipate that Cipher Pharmaceuticals will post ($0.28) EPS for the current fiscal year.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA.

5 Day Chart for NASDAQ:CPHR

Receive News & Stock Ratings for Cipher Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.